Clinical Pharmacology of Pemafibrate Extended-release Formulation in Patients with Hypertriglyceridemia-A Phase 2, Multicenter, Active-controlled, Randomized, Single-blind, Crossover Study

Overview

Journal J Atheroscler Thromb

Date 2024 Sep 25

PMID 39322570

Authors

Shizuya Yamashita

Eiichi Araki

Hidenori Arai

Koutaro Yokote

Ryohei Tanigawa

Ayumi Saito

Hideki Suganami

Sara Minamikawa

Shun Ishibashi

Affiliations

Soon will be listed here.

Abstract

Aims: Efficacy, safety, and pharmacokinetics of the selective PPARα modulator pemafibrate as once-daily extended-release (XR) tablets were compared with those of twice-daily immediate-release (IR) tablets in patients with hypertriglyceridemia.

Methods: A multicenter, randomized, single-blind, active-controlled crossover, phase 2 clinical pharmacology study was performed in patients with hypertriglyceridemia. Patients were randomly assigned to IR 0.2 mg/day, XR 0.4 mg/day, or XR 0.8 mg/day before/after meals (fasted/fed) and treated for a total of eight weeks. The primary endpoint was percentage change in fasting serum triglycerides (TG).

Results: Of 63 randomized patients, 60 received the study drug. Patients were 78.3% male, mean age (±SD) 57.5±9.8 years, BMI 25.5±3.7 kg/m, and fasting TG 221.3±68.1 mg/dL. Fasting serum TG decreased significantly from baseline in all groups (LS mean [95% CI];-43.6 [-47.7, -39.5] % for IR 0.2 mg/day, -41.1 [-45.1, -37.0] % for XR 0.4mg/day, -39.7 [-43.8, -35.6] % for XR 0.8 mg/day), indicating that XR 0.4 and XR 0.8 mg/day were not inferior to IR 0.2 mg/day. TG-lowering effects tended to be stronger for fed than fasted administration. MRT, t, and t were longer for XR than for IR. Adverse events showed no major inter-group differences: 12.5% (5/40 patients) for IR 0.2, 17.5% (7/40) for XR 0.4, and 20.0% (8/40) for XR 0.8 mg/day.

Conclusions: In patients with hypertriglyceridemia, XR substantially lowered TG at all doses, with maximum effectiveness at 0.4 mg/day, the dose approved in Japan, to a level comparable to IR 0.2 mg/day. There were no safety concerns up to 0.8 mg/day.

References

Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S . Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2017; 12(1):173-184. DOI: 10.1016/j.jacl.2017.10.006. View

Fruchart J . Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol. 2013; 12:82. PMC: 3682868. DOI: 10.1186/1475-2840-12-82. View

Imano H, Noda H, Kitamura A, Sato S, Kiyama M, Sankai T . Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Prev Med. 2011; 52(5):381-6. DOI: 10.1016/j.ypmed.2011.02.019. View

Van Regemorter E, Jadoul M, Gillion V . Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2023; 388(10):954-955. DOI: 10.1056/NEJMc2216470. View

Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S . Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. J Atheroscler Thromb. 2018; 25(6):521-538. PMC: 6005227. DOI: 10.5551/jat.44412. View

Arai H, Yamashita S, Araki E, Yokote K, Tanigawa R, Saito A . Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial. J Atheroscler Thromb. 2024; 31(11):1517-1538. PMC: 11537784. DOI: 10.5551/jat.64677. View

Yamashita S, Arai H, Yokote K, Araki E, Matsushita M, Nojima T . Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. Int J Mol Sci. 2019; 20(22). PMC: 6888510. DOI: 10.3390/ijms20225537. View

Lim S, Park Y, Sakuma I, Kon Koh K . How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol. Int J Cardiol. 2012; 166(1):8-14. DOI: 10.1016/j.ijcard.2012.03.127. View

Yamashita S, Arai H, Yokote K, Araki E, Suganami H, Ishibashi S . Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. J Clin Lipidol. 2018; 12(5):1267-1279.e4. DOI: 10.1016/j.jacl.2018.06.010. View

10.

Hottelart C, El Esper N, Rose F, Achard J, Fournier A . Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002; 92(3):536-41. DOI: 10.1159/000064083. View

11.

Pradhan A, Glynn R, Fruchart J, MacFadyen J, Zaharris E, Everett B . Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022; 387(21):1923-1934. DOI: 10.1056/NEJMoa2210645. View

12.

Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H . Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016; 249:36-43. DOI: 10.1016/j.atherosclerosis.2016.02.029. View

13.

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082-e1143. PMC: 7403606. DOI: 10.1161/CIR.0000000000000625. View

14.

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S . Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2006; 115(4):450-8. DOI: 10.1161/CIRCULATIONAHA.106.637793. View

15.

Sahebkar A, Chew G, Watts G . New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014; 15(4):493-503. DOI: 10.1517/14656566.2014.876992. View

16.

Claxton A, Cramer J, Pierce C . A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1296-310. DOI: 10.1016/s0149-2918(01)80109-0. View

17.

Jansen H, Samani N, Schunkert H . Mendelian randomization studies in coronary artery disease. Eur Heart J. 2014; 35(29):1917-24. DOI: 10.1093/eurheartj/ehu208. View

18.

Attridge R, Frei C, Ryan L, Koeller J, Linn W . Fenofibrate-associated nephrotoxicity: a review of current evidence. Am J Health Syst Pharm. 2013; 70(14):1219-25. DOI: 10.2146/ajhp120131. View

19.

Pawlak M, Lefebvre P, Staels B . Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2014; 62(3):720-33. DOI: 10.1016/j.jhep.2014.10.039. View

20.

Yamashita S, Rizzo M, Su T, Masuda D . Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis. Metabolites. 2023; 13(5). PMC: 10221566. DOI: 10.3390/metabo13050626. View